ZyVersa Therapeutics’ Shareholder Approvals and Director Elections
Company Announcements

ZyVersa Therapeutics’ Shareholder Approvals and Director Elections

An announcement from ZyVersa Therapeutics ( (ZVSA) ) is now available.

ZyVersa Therapeutics’ recent annual meeting saw key shareholder approvals, including the expansion of the 2022 Omnibus Equity Incentive Plan, boosting shares reserved for issuance by 150,000. Stockholders elected Min Chul Park, Ph.D. as a Class II director and ratified Marcum LLP as the independent auditor. Additionally, they approved the issuance of 478,600 shares linked to certain warrants, aligning with Nasdaq rules.

Find detailed analytics on ZVSA stock on TipRanks’ Stock Analysis page.

Related Articles
Sheryl Sheth3 Penny Stocks to Watch Now, 11/7/24
TheFlyZyVersa Therapeutics highlights published data on islet beta cell function
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App